Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PBM “transparency” lawsuit

Executive Summary

The Pharmaceutical Care Management Association files suit June 29 in Washington, D.C. federal court to block enforcement of the District's "AccessRx Act of 2004," enacted in May. The law requires full disclosure of PBMs' fees and financial terms between PBMs and drug companies, designates PBMs as fiduciaries, and requires pass through of all payments and discounts from manufacturers. The association contends that D.C.'s law violates the Commerce and Takings Clauses of the U.S. Constitution and that it is preempted by the federal Employee Retirement Income Security Act. A Maine federal court judge granted a preliminary injunction in March against a similar provision in that state (1"The Pink Sheet" March 15, 2004, p. 17)....
Advertisement

Related Content

PBM Regulation In Maine Blocked By Federal Court; ERISA Preempts State
PBM Regulation In Maine Blocked By Federal Court; ERISA Preempts State

Topics

Advertisement
UsernamePublicRestriction

Register

PS044296

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel